Effect of Y- box binding protein 1 overexpression on the prognosis of patients with intrahepatic cholangiocarcinoma undergoing postoperative adjuvant chemotherapy
-
摘要: 目的探讨Y-box结合蛋白(YB)1过表达与肝内胆管癌患者术后辅助化疗预后的关系。方法收集2010年1月-2015年1月于安徽医科大学第一附属医院行手术治疗并辅助术后化疗的58例肝内胆管癌患者的石蜡标本。使用免疫组化方法检测肝内胆管癌组织中YB-1表达情况,使用噻唑蓝方法检测YB-1质粒转染肝内胆管癌细胞对吉西他滨药物敏感性的改变。q PCR检测YB-1质粒转染肝内胆管癌细胞后多药耐受基因表达改变情况。计量资料2组间比较采用独立样本t检验,多组间比较采用单因素方差分析;计数资料组间比较采用χ2检验;Kaplan-Meier方法计算生存曲线,生存分析采用log-rank检验。结果58例患者中44例(75.9%)患者YB-1在肝内胆管癌组织细胞胞浆中呈高表达(YB-1胞浆阳性组),14例(24.1%)YB-1胞浆阴性(YB-1胞浆阴性组);44例YB-1胞浆阳性患者中有18例(40.9%)癌组织的细胞中出现YB-1核染色阳性(YB-1胞核阳性组),其余40例为YB-1胞核阴性组。YB-1胞核阴性组患者术后辅助化疗生存时间显著长于YB-1胞核阳性组患者(63个月vs 2...Abstract: Objective To investigate the association between Y- box binding protein 1( YB- 1) overexpression and the prognosis of patients with intrahepatic cholangiocarcinoma( ICC) undergoing postoperative adjuvant chemotherapy.Methods The paraffin- embedded specimens were collected from 58 patients with ICC who underwent surgical treatment and postoperative adjuvant chemotherapy in The First Affiliated Hospital of Anhui Medical University from January 2010 to January 2015.Immunohistochemistry was used to measure the expression of YB- 1 in ICC tissue;after ICC cells were transfected with YB- 1 plasmid,the thiazolyl blue method was used to observe the change in gemcitabine sensitivity,and q PCR was used to observe the changes in the expression of multidrug resistance genes.The independent samples t- test was used for comparison of continuous data between two groups and a one- way analysis of variance was used for comparison of continuous data between multiple groups;the chi- square test was used for comparison of categorical data between groups.The Kaplan-Meier method was used to calculate survival rates and the log- rank test was used for survival difference analysis.Results Among the 58 patients,44( 75.9%) had high expression of YB- 1 in the cytoplasm of ICC cells( cytoplasm YB- 1 positive group) and 14( 24.1%)had no expression of YB- 1 in the cytoplasm of ICC cells( cytoplasm YB- 1 negative group).Of all patients in the cytoplasm YB- 1 positive group,18( 40.9%) also had positive nuclear expression of YB- 1( nuclear YB- 1 positive group);the other 40 patients had no nuclear expression of YB- 1( nuclear YB- 1 negative group).The nuclear YB- 1 negative group had a significantly longer survival time than the nuclear YB- 1 positive group( 63 months vs 28 months,χ~2= 17.99,P < 0.05).In the control plasmid group,the half- maximal inhibitory concentration( IC_(50)) of gemcitabine in HCCC- 9810 cells was 0.054 μmol,and in the p SG5- YB- 1 plasma transfection group,IC_(50) increased to 0.460 μmol after YB- 1 overexpression,which was 10 times higher than that in control plasmid group( P < 0.05).There was a significant increase in the YB- 1 transcriptional level after HCCC- 9810 cells were transfected with p SG5- YB- 1 plasmids( t =19.02,P < 0.05).After YB- 1 overexpression,HCCC- 9810 cells had significant increases in the transcriptional levels of multidrug resistance protein 1( MDR1) and multidrug resistance- associated protein 1( MRP1)( t = 13.34 and 11.35,both P < 0.05).Conclusion YB- 1 overexpression can be found in most ICC tissues,and nuclear positive expression of YB- 1 may indicate the poor effect of postoperative adjuvant chemotherapy,which may be associated with the increase in multidrug resistance after the expression of MDR1 and MRP1.
-
Key words:
- biliary tract neoplasms /
- Y-box-binding protein 1 /
- drug tolerance /
- prognosis
-
[1]LYABIN DN,ELISEEVA IA,OVCHINNIKOV LP.YB-1 protein:functions and regulation[J].Wiley Interdiscip Rev RNA,2014,5(1):95-110. [2]ELISEEVA IA,KIM ER,GURYANOV SG,et al.Y-box-binding protein 1(YB-1)and its functions[J].Biochemistry(Mosc),2011,76(13):1402-1433. [3]ZHOU X,ZANG H,LIU HL.An excerpt of intrahepatic cholangiocarcinoma:expert consensus statement[J].J Clin Hepatol,2015,31(10):1584-1587.(in Chinese)周霞,臧红,刘鸿凌.《2014年美国肝胆胰学会共识声明:肝内胆管癌管理》摘译[J].临床肝胆病杂志,2015,31(10):1584-1587. [4]RAZUMILAVA N,GORES GJ.Classification,diagnosis,and management of cholangiocarcinoma[J].Clin Gastroenterol Hepatol,2013,11(1):13-21. [5]WANG X,LI XC.Research advances in palliative treatment of cholangiocarcinoma[J].J Clin Hepatol,2016,32(5):1022-1025.(in Chinese)王荇,李相成.胆管癌姑息治疗的研究进展[J].临床肝胆病杂志,2016,32(5):1022-1025. [6]KACHALAKI S,EBRAHIMI M,MOHAMED KHOSROSHAHI L,et al.Cancer chemoresistance;biochemical and molecular aspects:a brief overview[J].Eur J Pharm Sci,2016,89:20-30. [7]LI W,ZHANG H,ASSARAF YG,et al.Overcoming ABC transporter-mediated multidrug resistance:molecular mechanisms and novel therapeutic drug strategies[J].Drug Resist Updat,2016,27:14-29. [8]YASEN M,KAJINO K,KANO S,et al.The up-regulation of Y-box binding proteins(DNA binding protein A and Y-box binding protein-1)as prognostic markers of hepatocellular carcinoma[J].Clin Cancer Res,2005,11(20):7354-7361. [9]SHEN DY,ZHANG W,ZENG X,et al.Inhibition of Wnt/betacatenin signaling downregulates P-glycoprotein and reverses multi-drug resistance of cholangiocarcinoma[J].Cancer Sci,2013,104(10):1303-1308. [10]FUJITA T,ITO K,IZUMI H,et al.Increased nuclear localization of transcription factor Y-box binding protein 1 accompanied by up-regulation of P-glycoprotein in breast cancer pretreated with paclitaxel[J].Clin Cancer Res,2005,11(24 Pt 1):8837-8844. [11]XU W,ZHOU L,QIN R,et al.Nuclear expression of YB-1 in diffuse large B-cell lymphoma:correlation with disease activity and patient outcome[J].Eur J Haematol,2009,83(4):313-319. [12]ODA Y,OHISHI Y,BASAKI Y,et al.Prognostic implications of the nuclear localization of Y-box-binding protein-1 and CXCR4expression in ovarian cancer:their correlation with activated Akt,LRP/MVP and P-glycoprotein expression[J].Cancer Sci,2007,98(7):1020-1026. [13]VAIMAN AV,STROMSKAYA TP,RYBALKINA EY,et al.Intracellular localization and content of YB-1 protein in multidrug resistant tumor cells[J].Biochemistry(Mosc),2006,71(2):146-154. [14]STEIN U,JRCHOTT K,WALTHER W,et al.Hyperthermiainduced nuclear translocation of transcription factor YB-1 leads to enhanced expression of multidrug resistance-related ABC transporters[J].J Biol Chem,2001,276(30):28562-28569. 期刊类型引用(10)
1. 贺书杰. 早期手术治疗胆源性急性胰腺炎患者的临床疗效. 系统医学. 2024(04): 137-140 . 百度学术
2. 汪芝欢,徐燕芳,汪志刚. 清胰解毒通腑汤保留灌肠联合芒硝外敷治疗急性胰腺炎31例. 中国中医药科技. 2024(03): 543-545 . 百度学术
3. 吴迪,代大华,梁文美,付豹,傅小云. 妊娠期急性胰腺炎的临床特征及危险因素分析. 临床肝胆病杂志. 2024(05): 1009-1015 . 本站查看
4. 王宏,安莹,闫铁静,陆勇,王海涛. 降脂消胰汤内服与灌肠联合西药治疗高脂血症性胰腺炎疗效及对患者血脂、凝血功能的影响. 陕西中医. 2024(06): 785-788 . 百度学术
5. 陈宇,李响,宁佳曦,王雪,杨适,王忠琼. 高脂血症性急性胰腺炎的临床特征及其并发全身炎症反应综合征的预测. 现代消化及介入诊疗. 2023(03): 300-304 . 百度学术
6. 田光芳,张渊智,张绍敏. 生大黄保留灌肠治疗急性胰腺炎临床观察. 光明中医. 2022(20): 3739-3743 . 百度学术
7. 徐文倩,郭敏,王晓,吴瑶麒,张近远,李合国. 急性胰腺炎肝损伤的分子机制. 临床肝胆病杂志. 2022(11): 2663-2668 . 本站查看
8. 贾清,黄小华,明兵,唐玲玲,胡云涛,刘琢玉. 基于CT灌注动脉期的纹理分析鉴别胆源性与高脂血症性急性胰腺炎的研究. 中国医学计算机成像杂志. 2022(06): 603-608 . 百度学术
9. 赵秀芬,李影,梁世耀,吴程为,卜斌茹,林陈婵. 重症急性胰腺炎患者区域动脉灌注导管规范化护理方案的构建?. 肝胆胰外科杂志. 2021(02): 109-113 . 百度学术
10. 尚鑫,王静. 重症急性胰腺炎预后危险因素分析. 临床医学研究与实践. 2021(17): 28-30 . 百度学术
其他类型引用(7)
-